Lancet. 2020 Jul 4;396(10243):27-38. doi: 10.1016/S0140-6736(20)31182-X. Epub 2020 May 29.
The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on postoperative recovery needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. This study reports 30-day mortality and pulmonary complication rates in patients with perioperative SARS-CoV-2 infection.
This international, multicentre, cohort study at 235 hospitals in 24 countries included all patients undergoing surgery who had SARS-CoV-2 infection confirmed within 7 days before or 30 days after surgery. The primary outcome measure was 30-day postoperative mortality and was assessed in all enrolled patients. The main secondary outcome measure was pulmonary complications, defined as pneumonia, acute respiratory distress syndrome, or unexpected postoperative ventilation.
This analysis includes 1128 patients who had surgery between Jan 1 and March 31, 2020, of whom 835 (74·0%) had emergency surgery and 280 (24·8%) had elective surgery. SARS-CoV-2 infection was confirmed preoperatively in 294 (26·1%) patients. 30-day mortality was 23·8% (268 of 1128). Pulmonary complications occurred in 577 (51·2%) of 1128 patients; 30-day mortality in these patients was 38·0% (219 of 577), accounting for 81·7% (219 of 268) of all deaths. In adjusted analyses, 30-day mortality was associated with male sex (odds ratio 1·75 [95% CI 1·28-2·40], p<0·0001), age 70 years or older versus younger than 70 years (2·30 [1·65-3·22], p<0·0001), American Society of Anesthesiologists grades 3-5 versus grades 1-2 (2·35 [1·57-3·53], p<0·0001), malignant versus benign or obstetric diagnosis (1·55 [1·01-2·39], p=0·046), emergency versus elective surgery (1·67 [1·06-2·63], p=0·026), and major versus minor surgery (1·52 [1·01-2·31], p=0·047).
Postoperative pulmonary complications occur in half of patients with perioperative SARS-CoV-2 infection and are associated with high mortality. Thresholds for surgery during the COVID-19 pandemic should be higher than during normal practice, particularly in men aged 70 years and older. Consideration should be given for postponing non-urgent procedures and promoting non-operative treatment to delay or avoid the need for surgery.
National Institute for Health Research (NIHR), Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, NIHR Academy, Sarcoma UK, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research.
需要了解严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)对术后恢复的影响,以便为 COVID-19 大流行期间和之后的临床决策提供信息。本研究报告了围手术期 SARS-CoV-2 感染患者的 30 天死亡率和肺部并发症发生率。
本研究为国际多中心队列研究,在 24 个国家的 235 家医院开展,纳入所有在手术前 7 天内或手术后 30 天内确诊 SARS-CoV-2 感染的手术患者。主要结局指标为术后 30 天的死亡率,所有入组患者均进行评估。主要次要结局指标为肺部并发症,定义为肺炎、急性呼吸窘迫综合征或意外术后通气。
本分析纳入了 2020 年 1 月 1 日至 3 月 31 日期间接受手术的 1128 例患者,其中 835 例(74.0%)为急诊手术,280 例(24.8%)为择期手术。术前确诊 SARS-CoV-2 感染的患者有 294 例(26.1%)。1128 例患者中,30 天死亡率为 23.8%(268 例)。在 1128 例患者中,577 例(51.2%)发生肺部并发症;这些患者的 30 天死亡率为 38.0%(219 例),占所有死亡人数的 81.7%(219 例)。在调整分析中,30 天死亡率与男性(比值比 1.75[95%CI 1.28-2.40],p<0.0001)、70 岁及以上(2.30[1.65-3.22],p<0.0001)、美国麻醉医师协会(ASA)分级 3-5 级(2.35[1.57-3.53],p<0.0001)、恶性(1.55[1.01-2.39],p=0.046)、急诊手术(1.67[1.06-2.63],p=0.026)、大手术(1.52[1.01-2.31],p=0.047)有关。
围手术期 SARS-CoV-2 感染患者中有一半发生术后肺部并发症,且死亡率较高。COVID-19 大流行期间手术的阈值应高于正常水平,特别是 70 岁及以上的男性。应考虑推迟非紧急手术,并提倡非手术治疗,以延迟或避免手术的需要。
英国国家卫生研究院(NIHR)、英国大肠肛门病学会、肠道和癌症研究、肠道疾病研究基金会、上消化道外科医师协会、英国外科肿瘤学会、英国妇科癌症学会、欧洲结直肠外科学会、NIHR 学会、肉瘤英国、大不列颠和爱尔兰血管学会、约克郡癌症研究。